Parkinsons Disease

LINC00943[LncRNA]

miR-7-5p[miRNA]

CXCL12[mRNA]

SK-N-SH cells

Homo sapiens (human)

Genes Genomics. 2021 Jul;43(7):797-805. doi: 10.1007/s13258-021-01084-1. Epub 2021 Apr 22.

LINC00943 knockdown exerts neuroprotective effects in Parkinson's disease through regulates CXCL12 expression by sponging miR-7-5p.

Flow cytometry assay;qPCR;RT-qPCR;RIP assay;RNA immunoprecipitation;Western blot;Flow Cytometry assay;RNA immunoprecipitation;

BACKGROUND: Parkinson's disease (PD) is a common neurodegenerative movement disorder, but the pathogenesis is still unclear. Long non-coding RNAs (lncRNAs) have been reported to play a prominent role in PD. OBJECTIVE: This study is designed to explore the role and mechanism of long intergenic non-coding RNA 00943 (LINC00943) in the N-methyl-4-phenylpyridine (MPP(+))-inducted PD model. METHODS: LINC00943, microRNA-7-5p (miR-7-5p), and the chemokine (C-X-C motif) ligand 12 (CXCL12, also referred to as SDF-1) level were examined by real-time quantitative polymerase chain reaction (RT-qPCR). Cell viability and apoptosis were analyzed by 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2-H-tetrazolium bromide (MTT), and flow cytometry assays, severally. Protein levels of interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), and CXCL12 were assessed by western blot assay. The ROS generation and SOD activity were detected by the corresponding kits. The binding relationship between miR-7-5p and LINC00943 or CXCL12 was predicted by Starbase and then verified by a dual-luciferase reporter and RNA Immunoprecipitation (RIP) assays. RESULTS: LINC00943 and CXCL12 were increased, and miR-7-5p was decreased in MPP(+)-inducted SK-N-SH cells. LINC00943 silencing promoted cell viability, and repressed apoptosis and the inflammatory response in MPP(+)-treated SK-N-SH cells. The mechanical analysis discovered that LINC00943 acted as a sponge of miR-7-5p to regulate CXCL12 expression. CONCLUSIONS: LINC00943 knockdown could attenuate MPP(+)-triggered neuron injury by regulating the miR-7-5p/CXCL12 axis, hinting at a promising therapeutic target for PD treatment.